Vincerx Pharma Inc Stock price
Is Vincerx Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Vincerx Pharma Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Vincerx Pharma Inc forecast:
Analyst Opinions
7 Analysts have issued a Vincerx Pharma Inc forecast:
Don't miss a Thing! We will send you all news about Vincerx Pharma Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed Hamdy, Raquel Izumi, Tom Thomas, Stuart Hwang, and John Byrd in 2018 and is headquartered in Palo Alto, CA.
| Head office | United States |
| CEO | Dr. Izumi |
| Employees | 13 |
| Founded | 2018 |
| Website | vincerx.com |


